Literature DB >> 9528823

Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not.

J M Ossewaarde1, E J Feskens, A De Vries, C E Vallinga, D Kromhout.   

Abstract

To test the hypothesis that chronic infection with Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus is associated with coronary heart disease risk in elderly men, a nested case-control study in a cohort investigated in 1985 and 1990 in the town of Zutphen, The Netherlands, was designed. Fifty-four cases with a first diagnosed coronary event between 1985 and 1990, and 108 age-matched control subjects free of coronary heart disease during follow up were included in the study. The overall prevalence of antibodies to cytomegalovirus was 74.7%, to H. pylori 75.9% and to C. pneumoniae 84.0%. A high level of antibodies to C. pneumoniae was associated with an increased coronary heart disease risk (OR = 2.76; 95% CI = 1.31-5.81). This association was stronger in cases developing both myocardial infarction and angina pectoris, than in cases developing only one of these. This association was independent of potential confounders. Antibodies to cytomegalovirus or H. pylori were not associated with coronary heart disease risk. These results support the hypothesis of a role of chronic C. pneumoniae infections in the immunopathogenesis of atherosclerosis.

Entities:  

Mesh:

Year:  1998        PMID: 9528823      PMCID: PMC2809353          DOI: 10.1017/s0950268897008303

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  29 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis.

Authors:  J D Rutherford
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Cytomegalovirus seropositivity and incident ischaemic heart disease in the Caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; B K Butland; P M Sweetnam; P C Elwood
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

3.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; L Ballam; J Morris; B K Butland; P M Sweetnam; P C Elwood
Journal:  BMJ       Date:  1999-04-17

Review 4.  Microorganisms in the aetiology of atherosclerosis.

Authors:  S A Morré; W Stooker; W K Lagrand; A J van den Brule; H W Niessen
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

Review 5.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 6.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

7.  Cytomegalovirus infection and coronary heart disease risk: a meta-analysis.

Authors:  Ya-Nan Ji; Li An; Ping Zhan; Xiao-Hu Chen
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

Review 8.  Extradigestive manifestations of Helicobacter pylori gastric infection.

Authors:  A Gasbarrini; F Franceschi; A Armuzzi; V Ojetti; M Candelli; E S Torre; A De Lorenzo; M Anti; S Pretolani; G Gasbarrini
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 9.  Chronic infections and atherosclerosis/thrombosis.

Authors:  Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

10.  Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Moyses Szklo; Jingzhong Ding; Michael Y Tsai; Mary Cushman; Joseph F Polak; João Lima; R Graham Barr; A Richey Sharrett
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2009-10       Impact factor: 2.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.